Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q1 2022 · 10-Q
Revenue$117.28M$117.28M+31.7% vs Q1 2021 Net Income$60.11M$60.11M+115.5% vs Q1 2021 EPS Diluted$0.43$0.43+126.3% vs Q1 2021 Operating Income$75,670,000+49.1% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
Free Cash Flowderived$47,307,000−18.5% Margins · derivedOperating margin64.5%+7.5 pt vs Q1 2021
Net margin51.3%+19.9 pt vs Q1 2021
ended Mar 31, 2022 · filed May 10, 2022 · 40 d after period end